Medtech Insight

Lucid Diagnostics Seeks Clear Path To US Reimbursement For Esophageal Precancer Test

Test Targets Unmet Need For GERD Patients At Risk Of Developing Precancer And Cancer

11 Jul 2024

Lishan Aklog, CEO of New York-based Lucid Diagnostics, has a long-term vision to provide the paradigm of prevention-to-treatment care for esophageal cancer. In the short term, the company anticipates a favorable outcome from an upcoming pivotal Medicare assessment of its early screening technology.

Esophageal Cancer vector — • Source: Shutterstock

In over three decades in medicine, Lishan Aklog has experienced breakthrough moments as a heart surgeon in the US, UK and France, and since 2018, as chair and CEO ofLucid Diagnostics, Inc., which is a subsidiary of PAVmed Inc..

But potentially the biggest moment is yet to arrive: Lucid Diagnostics will hold a pre-submission meeting with Medicare’s MolDX program...